Initial Dosing and Titration of Tirzepatide

Rationale for Gradual Titration

Gradual dose titration is essential to minimize gastrointestinal adverse effects, which are common with GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, as recommended by the American Gastroenterological Association 1, 2
Tirzepatide has a different mechanism of action than semaglutide, acting as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, according to the American Diabetes Association 3, 4
Even though patients may have developed tolerance to semaglutide's GI effects, tirzepatide's dual mechanism may cause new or different GI side effects, as noted by the American Society of Anesthesiologists 5

Gastrointestinal side effects are common with both medications but may be more pronounced with tirzepatide, as reported by the American Diabetes Association 4, 6
Common GI side effects include nausea, vomiting, diarrhea, and esophageal reflux, according to the American Diabetes Association 4, 6
Tirzepatide may delay gastric emptying, which could affect the absorption of oral medications, as warned by the American Society of Anesthesiologists 5, 6

Tirzepatide has demonstrated superior efficacy in weight reduction and glycemic control compared to semaglutide in clinical trials, with a weight loss of 14.7% compared to 9.6% with semaglutide, as reported by the American Diabetes Association 3, 7

Both medications carry a black box warning regarding the risk of thyroid C-cell tumors in rodents (human relevance not determined), as cautioned by the American Diabetes Association 4, 6
Do not use in individuals with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, as advised by the American Diabetes Association 4
Use caution in patients with kidney disease when initiating or increasing dose due to potential risk of acute kidney injury, as recommended by the American Diabetes Association 6

Assess efficacy and safety at least monthly for the first 3 months and at least quarterly thereafter, as recommended by the American Diabetes Association 8
Monitor for gastrointestinal disorders including severe constipation and small-bowel obstruction/ileus progression, as advised by the American Diabetes Association 4
Be alert for potential cholelithiasis and gallstone-related complications, as warned by the American Diabetes Association 4, 6

Gradual dose titration of Mounjaro is essential to minimize gastrointestinal adverse effects, which remain common despite prior GLP-1 RA use, in patients with a history of semaglutide treatment, according to Gastroenterology guidelines 9
The American Gastroenterological Association recommends starting Mounjaro at the time of the next scheduled Ozempic dose, with no washout period required, given the once-weekly dosing schedule of both medications, as reported in Gastroenterology 9

The American Diabetes Association recommends maximum maintenance doses of Mounjaro are 10 mg or 15 mg weekly, depending on efficacy and tolerability 10, 11

The American College of Cardiology suggests counseling patients to eat smaller portions during the titration phase to minimize gastrointestinal side effects 12
The American College of Cardiology recommends reassuring patients that nausea is typically self-limited and does not indicate gastrointestinal pathology 12
The American College of Cardiology advises to begin again at 2.5 mg with gradual up-titration if treatment must be suspended and restarted, to avoid recurrent symptoms 12
The American College of Cardiology recommends using caution in patients with clinically significant gastroparesis history 12

The American College of Cardiology suggests reducing sulfonylurea doses by 50% or discontinue entirely when initiating tirzepatide to reduce hypoglycemia risk 12
The American College of Cardiology recommends decreasing basal insulin by 20-30% if the patient is on insulin therapy to minimize hypoglycemia risk 12

The cost of tirzepatide is approximately $1,283 per month (AWP for 15 mg) versus $1,162 for semaglutide 2 mg, according to the American Diabetes Association 10
The Journal of the American Medical Association notes that insurance coverage may be restricted for Mounjaro and Ozempic, and Medicare excludes coverage for obesity indication alone 13
The Journal of the American Medical Association reports that global shortages of GLP-1 receptor agonists exist, and availability may be limited 13

The American College of Cardiology recommends monitoring blood glucose more closely for the first 4 weeks of therapy, particularly in patients on background insulin, sulfonylurea, or glinide therapy 14